Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease

Kidney International, Supplement

Volumn 68, Issue 96, 2005, Pages

  Quarles, L Darryl ^a  

^a Kidney Institute   (United States)

Author keywords

Calcimimetics; Hyperphosphatemia; Parathyroid hormone; Renal osteodystrophy; Vitamin D

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D DERIVATIVE; PHOSPHATE BINDING AGENT; PHOSPHORUS; STEROL DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADJUVANT THERAPY; ALLOSTERISM; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MEDICAL LITERATURE; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VITAMIN SUPPLEMENTATION; BLOOD VESSEL CALCIFICATION; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG STRUCTURE; HEMODIALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PARATHYROID HORMONE RELEASE; RENAL REPLACEMENT THERAPY; VITAMIN D DEFICIENCY; CHRONIC DISEASE; DRUG EFFECT; KIDNEY DISEASE; REVIEW;

CHRONIC DISEASE; CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; NAPHTHALENES; PRACTICE GUIDELINES; RECEPTORS, CALCIUM-SENSING;

EID: 26044450922     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00451.x     Document Type: Conference Paper

References (15)

1. QUARLES LD: Introduction: Emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients. Adv Ren Replace Ther 9:153-158, 2002
2. INDRIDASON OS, HEATH H 3rd, KHOSLA S, et al: Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 50:1663-1671, 1996
3. BROWN EM, GAMBA G, RICCARDI D, et al: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
4. AMLING M, PRIEMEL M, HOLZMANN T, et al: Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 140:4982-4987, 1999
5. SLATOPOLSKY E, BROWN A, DUSSO A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37(Suppl 2):S54-S57, 2001
6. INDRIDASON OS, QUARLES LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57:282-292, 2000
7. PRICE PA, FAUS SA, WILLIAMSON MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20:317-327, 2000
8. CHERTOW GM, BURKE SK, RAGGI P, TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
9. URIBARRI J, THE NATIONAL KIDNEY FOUNDATION: K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: Some therapeutic implications. Semin Dial 17:349-350, 2004
10. MOE SM, CHERTOW GM, COBURN JW, et al: Achieving NKF-K/DOQI(™) bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760-771, 2005
11. MALBERTI F, MARCELLI D, CONTE F, et al: Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 12:1242-1248, 2001
12. NEMETH EF, STEEFEY ME, HAMMERLAND LG, et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045, 1998
13. COLLOTON M, SHATZEN E, MILLER G, et al: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467-476, 2005
14. QUARLES LD, SHERRARD DJ, ADLER S, et al: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583, 2003
15. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004